SWTX: SpringWorks Therapeutics, Inc. Stock

by  •  • Comments Off on SWTX: SpringWorks Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 3,503.35
Enterprise Value ($M) 3,439.58
Book Value ($M) 417.39
Book Value / Share 5.57
Price / Book 8.39
NCAV ($M) 268.36
NCAV / Share 3.58
Price / NCAV 13.05

Profitability (mra)
Return on Invested Capital (ROIC) -0.60
Return on Assets (ROA) -0.39
Return on Equity (ROE) -0.45

Liquidity (mrq)
Quick Ratio 4.18
Current Ratio 4.33

Balance Sheet (mrq) ($M)
Current Assets 356.32
Assets 505.36
Liabilities 87.96
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 191.59
Operating Income -278.13
Net Income -258.13

Cash Flow Statement (mra) ($M)
Cash From Operations -175.60
Cash from Investing 64.55
Cash from Financing 4.76

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-07 13G/A Fmr Llc 1.70 -88.36
02-14 13G/A Deep Track Capital, LP 4.65 -14.84
01-31 13G/A Vanguard Group Inc 9.62 18.59
10-25 13G/A Boxer Capital Management, LLC 4.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2025-02-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-04 475,042 4,735,563 10.03
2025-06-03 100,101 2,921,411 3.43
2025-06-02 233,610 4,765,678 4.90
2025-05-30 354,163 4,215,611 8.40

(click for more detail)

Similar Companies
STOK – Stoke Therapeutics, Inc. STTK – Shattuck Labs, Inc.
SVRA – Savara Inc. SYRE – Spyre Therapeutics, Inc.
TARS – Tarsus Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io